The firm hopes that ETX-636's dual mechanism inhibiting mutant PI3Kα will give it an edge over competing products on the market.

A panelist discusses the evolving role of prophylactic tocilizumab in reducing cytokine release syndrome during bispecific antibody therapy, enabling outpatient treatment and improving patient ...

Illumina said adding SomaLogic would support the company’s multiomics strategy and strengthen the value of its NovaSeq X ...

Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein ...

Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains ...

The global DNA data storage market size was valued at USD 77.56 million in 2024 and is poised to grow from USD 124.59 million by 2025 to reach USD 5524.86 million by 2033, reflecting a robust CAGR ...

INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.

June 26, 2025, is the 25th anniversary of the White House announcement of the first sequencing of the human genome, and July 28, 2025, marks the 30th anniversary of the publication of the first ...

A confirmatory phase 3 trial of lurbinectedin in patients with relapsed SCLC is ongoing (LAGOON; NCT05153239) after ATLANTIS, a phase 3 trial in relapsed SCLC with lurbinectedin plus doxorubicin, did ...

Recent collaborations highlight a growing interest in building a multiomics-based understanding of health and disease.